Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China

Jiang-Han Wang,Wen-Lian Chen,Jun-Min Li,Song-Fang Wu,Tian-Lu Chen,Yong-Mei Zhu,Wei-Na Zhang,Yang Li,Yun-Ping Qiu,Ai-Hua Zhao,Jian-Qing Mi,Jie Jin,Yun-Gui Wang,Qiu-Ling Ma,He Huang,De-Pei Wu,Qin-Rong Wang,Yan Li,Xiao-Jing Yan,Jin-Song Yan,Jian-Yong Li,Shuai Wang,Xiao-Jun Huang,Bing-Shun Wang,Wei Jia,Yang Shen,Zhu Chen,Sai-Juan Chen
DOI: https://doi.org/10.1073/pnas.1315558110
IF: 11.1
2013-01-01
Proceedings of the National Academy of Sciences
Abstract:Significance Acute myeloid leukemia (AML) consists of a group of hematopoietic malignancies with considerable diversities in clinical and biological features. Recently, not only genetic abnormalities but also “oncometabolites,” such as 2-hydroxyglutarate (2-HG), have been found to play a role in driving AML pathogenesis and serve as potential disease markers. In this study on a large cohort of AML, we found that the serum 2-HG level was increased in 62 of 367 (17%) cases with distinct hematologic and biological features. Survival analysis performed in 234 patients without prognostic cytogenetic markers showed that increased 2-HG level was a poor predictor, demonstrating the potential of serum 2-HG as an independent marker for outcome evaluation of AML.
What problem does this paper attempt to address?